- ProMIS Neurosciences (PMN) congratulates Biogen on FDA accelerated approval of aducanumab
- After two years of setbacks in the AD field, 2021 has seen significant progress and reason for optimism in the AD community
- The FDA approval of aducanumab offers further potential positive momentum for AD patients
- PMN310, is a humanized monoclonal antibody that binds with high affinity and selectivity to toxic oligomers of A, a root cause of AD
- ProMIS Neurosciences, Inc. is a development-stage biotechnology company
- ProMIS Neurosciences Inc. (PMN) is up 2.08 per cent, trading at C$0.245 per share at 12:10 pm ET
ProMIS Neurosciences (PMN) congratulates Biogen on the FDA’s accelerated approval of aducanumab for the treatment of Alzheimer’s Disease (AD).
After two years of setbacks in the AD field, 2021 has seen significant progress and reason for optimism in the AD community. Biogen’s June 7th FDA approval of aducanumab offers further potential positive momentum for AD patients.
“The approval of aducanumab marks the availability of the first disease-modifying therapy for AD, the sixth leading cause of death in the United States,” stated ProMIS Executive Chairman Eugene Williams.
“We congratulate Biogen on this important development for AD patients and their caregivers. We now anticipate accelerated interest and support for the development of next generation therapies, such as ProMIS’ PMN310 lead antibody therapeutic for AD. Using our proprietary discovery platform we were able to create an antibody that selectively targets the toxic oligomers of amyloid-beta (A) and avoids undesirable binding to non-toxic forms of amyloid. We believe this high degree of selectivity by PMN310 may offer significant differentiation in terms of efficacy and safety compared to the currently less selective antibody products.”
PMN310, is a humanized monoclonal antibody that binds with high affinity and selectivity to toxic oligomers of A, a recognized root cause of AD.
Importantly, PMN310 does not appreciably bind to A plaque or vascular deposits of A thereby reducing the likelihood of brain swelling (edema), a dose-limiting side effect observed with non-selective therapeutic antibodies that interact with A plaque.
ProMIS Neurosciences, Inc. is a development-stage biotechnology company focused on discovering and developing antibody therapeutics that target toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).
ProMIS Neurosciences Inc. (PMN) is up 2.08 per cent, trading at C$0.245 per share at 12:10 pm ET.